A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia
Teva Identifier
TV48125-PN-20028
ClinicalTrials.gov Identifier
NCT03965091
Study Status
Terminated
Trial Condition(s)
Fibromyalgia
Interventions
Drug: Fremanezumab - Dose A | Drug: Fremanezumab - Dose B | Drug: Placebo
Study Description
Primary objectives: The primary objective of the study is to estimate the treatment effect of fremanezumab administered subcutaneously in reducing pain in adult patients with FM. Secondary objectives: A secondary objective is to evaluate the effect of fremanezumab on other efficacy measures, including pain, quality of life, sleep, fatigue, improvement in health, physical functioning, and mood. Another secondary objective is to evaluate the safety and tolerability of fremanezumab administered subcutaneously in adult patients with FM.
The total duration of patient participation in the study is planned to be 21 weeks, consisting of a screening period of up to 5 weeks (ranging from 17 to 35 days), and a double-blind treatment period of 16 weeks.
You are about to leave the Teva Pharmaceuticals global website
The website you are about to access may be governed by different regional policies, regulations or advertising codes. Please be sure to read the privacy policy and terms of use of the websites that you visit.
Teva Pharmaceuticals is not responsible for the accuracy or compliance with laws of information on any third party websites.